Hypoglycemia is a serious complication for people with diabetes who are on medications such as sulfonylureas and insulin (1). Severe hypoglycemia can lead to seizures, declined cognitive function, cardiovascular events, and even death. Impaired awareness of hypoglycemia (IAH) makes matters much worse (2). Up to 25% of people with type 1 diabetes and up to 10% of people with type 2 diabetes who are on insulin have IAH (2). These individuals do not experience the typical symptoms of hypoglycemia because of autonomic failure; their glucagon or catecholamine levels may not increase to trigger hepatic glucose production in time.

Continuous glucose monitoring (CGM) systems are increasingly accessible and effective for hypoglycemia-prone people with type 1 or type 2 diabetes as a means of receiving real-time biofeedback and facilitating behavior change. CGM systems check glucose levels in interstitial fluid every 5 minutes. Alerts can be programmed...

You do not currently have access to this content.